|
Immune responses and clinical outcomes in STAND, a randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC) after local therapy failure. |
|
|
Honoraria - Dendreon; Janssen Biotech; Medivation; Sanofi |
Consulting or Advisory Role - Dendreon; Janssen Biotech; Medivation; Sanofi |
Research Funding - Aragon Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Cardinal Health |
|
|
Stock and Other Ownership Interests - Swan Medical |
Honoraria - Astellas Pharma; Bayer; Dendreon; Janssen; Medivation |
Consulting or Advisory Role - Astellas Pharma; Dendreon; Genomic Health; Janssen; Medivation; Myriad Pharmaceuticals |
Speakers' Bureau - Astellas Pharma; Dendreon; Medivation |
Research Funding - Amgen; Aquinox; Argos Therapeutics; Augmenix; Auxilium; Dendreon; Evidera; FKD Therapies; Genomic Health; Janssen; Medivation; Myriad Pharmaceuticals; Nymox; Orion; Pfizer; Takeda |
Expert Testimony - Takeda |
|
|
Stock and Other Ownership Interests - Pfizer |
Consulting or Advisory Role - McKinsey & Company; QPID Health |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Dendreon; Ferring; Janssen; Millennium; Pfizer; Sanofi |
Research Funding - Carolina Urologic Research Center |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Dendreon; Ferring; Janssen; Millennium; Pfizer; Sanofi |
|
|
|
Stock and Other Ownership Interests - Caris Life Sciences |
Honoraria - Abbvie; Bavarian Nordic; Dava Oncology; Endocyte; Mannkind; UpToDate |
Consulting or Advisory Role - Amgen; AVEO; BIND Biosciences; Janssen Biotech |
Speakers' Bureau - Bayer; Caris MPI; Dendreon; GlaxoSmithKline; Medivation; Millennium; Sanofi |
Research Funding - Endocyte (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Parexel (Inst); Progenics (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst) |
Travel, Accommodations, Expenses - Bayer/Onyx; Celgene; Dendreon; Exelixis; Genentech/Roche; Novartis; Pfizer; US Oncology |
|
|
Research Funding - Dendreon |
|
Johnathan Cartwright Maher |
|
Stock and Other Ownership Interests - Dendreon |
|
|
|
Stock and Other Ownership Interests - Dendreon |
Consulting or Advisory Role - KinDex |
|
|
|
Stock and Other Ownership Interests - Dendreon |
|
|
|
Stock and Other Ownership Interests - Dendreon |
Patents, Royalties, Other Intellectual Property - Dendreon |
|
|
Stock and Other Ownership Interests - Compugen; ImmuneXcite |
Consulting or Advisory Role - Bristol-Myers Squibb; Compugen; Dendreon; ImmuneXcite; Janssen; Pfizer; Roche Pharma AG |
Research Funding - Aduro Biotech; Bristol-Myers Squibb; Janssen |